Evaluation of Cladribine treatment in refractory celiac disease type II

doi:10.3748/wjg.v17.i4.506

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4992)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

506

HTML

4229

Figures (1-3)

135

Tables (1-2)

122

Sum=4992

Jan 28, 2011 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (54)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 28, 2011; 17(4): 506-513
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.506

Full Size Figure Download Figure

Figure 1 Schematic representation of intracellular pathways involved in 2-CdA cytotoxicity. (Adapted with permission from Borak, 2006). 2-CdA-MP: Cladribine monophosphate; 2-CdA-DP: Cladribine diphosphate; 2-CdA-TP: Cladribine triphosphate; dCK: Deoxycytidine kinase; 5’-NT: 5’-nucleotidase; hENT: Human equilibrative nucleoside transporter; hCNT: Human concentrative nucleoside transporter; AIF: Apoptosis inducing factor; APAF-1: Apoptotic protease activating factor; PARP: Poly (ADP-ribose) polymerase.

Citation: Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011; 17(4): 506-513
URL: https://www.wjgnet.com/1007-9327/full/v17/i4/506.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i4.506